Open questions in haemophilia, such as effectiveness of innovative therapies, clinical and patient‐reported outcomes (PROs), epidemiology and cost, await answers. The aim was to identify data attributes required and investigate… Click to show full abstract
Open questions in haemophilia, such as effectiveness of innovative therapies, clinical and patient‐reported outcomes (PROs), epidemiology and cost, await answers. The aim was to identify data attributes required and investigate the availability, appropriateness and accessibility of real‐world data (RWD) from German registries and secondary databases to answer the aforementioned questions.
               
Click one of the above tabs to view related content.